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A metalloproteomic analysis of interactions
between plasma proteins and zinc: elevated fatty
acid levels affect zinc distribution†
James P. C. Coverdale, ‡a James P. Barnett, ‡b Adamu H. Adamu,a
Ellie J. Griffiths,a Alan J. Stewart c and Claudia A. Blindauer *a
Serum albumin is a highly abundant plasma protein associated with the transport of metal ions, pharmaceuticals,
fatty acids and a variety of small molecules in the blood. Once thought of as a molecular ‘sponge’, mounting
evidence suggests that the albumin-facilitated transport of chemically diverse entities is not independent. One
such example is the transport of Zn2+ ions and non-esterified ‘free’ fatty acids (FFAs) by albumin, both of which
bind at high affinity sites located in close proximity. Our previous research suggests that their transport in blood
plasma is linked via an allosteric mechanism on serum albumin. In direct competition, albumin-bound FFAs
significantly decrease the binding capacity of albumin for Zn2+, with one of the predicted consequences being a
change in plasma/serum zinc speciation. Using liquid chromatography (LC), ICP-MS and fluorescence assays, our
work provides a quantitative assessment of this phenomenon, and finds that in the presence of high FFA
concentrations encountered in various physiological conditions, a significant proportion of albumin-bound Zn2+
is re-distributed amongst plasma/serum proteins. Using peptide mass fingerprinting and immunodetection, we
identify candidate acceptor proteins for Zn2+ liberated from albumin. These include histidine-rich glycoprotein
(HRG), a multifunctional protein associated with the regulation of blood coagulation, and members of the
complement system involved in the innate immune response. Our findings highlight how FFA-mediated changes
in extracellular metal speciation might contribute to the progression of certain pathological conditions.
Significance to metallomics
Building on previous evidence from single-protein model systems and computational simulations, this work provides a metalloproteomic assessment of serum/
plasma zinc speciation, and identifies a significant re-distribution of Zn2+ amongst serum/plasma proteins, as a consequence of increased free fatty acid levels.
Fluctuations in both serum free fatty acids and serum zinc have been independently associated with a plethora of diseases. This work now enhances our
understanding of how metalloproteomic approaches are vital in order to understand the bio-inorganic mechanisms at play. Moreover, our work also suggests
how metal ion speciation might even be affected in normal physiology, such as after the consumption of food or intense aerobic exercise.
Introduction
The importance of zinc as an essential micronutrient for all life
forms is well recognised. Increases of between 30–600% in crop
yields have been achieved solely by zinc fertilisation,1 as well as
dietary zinc supplementation being identified as a top priority
by the 2008 Copenhagen Consensus Conference for 80% of the
world’s 140 million malnourished children.2 As a Type II
nutrient,3 zinc directly affects multiple physiological processes
with deficiency leading to growth retardation, skin lesions,
diarrhoea, infertility, and compromised immune4 and cognitive
function.5 Milder zinc deficiency is also a risk factor for cardiomyo-
pathy and myocardial infarction.6 The pervasive effects of inade-
quate zinc supply occur not only because of the essentiality of zinc
for the function of hundreds of enzymes and thousands of
transcription factors,7,8 but also because zinc is a signalling agent,
and mediates and modulates bio-molecular interactions.9
Considering these multiple effects, it is perhaps at first
surprising that to plants and animals including humans, excess
zinc is not particularly toxic. However, the picture of zinc’s
apparent biological harmlessness disintegrates once the effects
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of elevated free Zn2+ concentrations on individual cells are
considered, as low micromolar concentrations are sufficient
to induce apoptotic or necrotic cell death pathways in a variety
of cell types.4,10 Many unicellular organisms are also highly
sensitive to Zn2+.11,12 It follows that for higher eukaryotes, zinc
toxicity is largely avoided by careful control of gastrointestinal
tract absorption and – crucially – regulation of extracellular free
Zn2+,13–15 ensuring its concentrations remain below the levels
at which it would begin to exert any cytotoxic effects.
It is well known that human blood plasma or serum contain
significant amounts of zinc (9.6–31.6 mM),16,17 alongside similar
quantities of iron (6.05–26.96 mM)18 and copper (17  6 mM),19
whilst only low-nanomolar amounts of manganese, cobalt and
molybdenum are present.20–22 Assuming a typical total amount
of body zinc of 2.7 g, and a plasma volume of 2.5 L, it can be
estimated that less than 0.2% of total body zinc is in the blood
plasma. Despite this minor proportion, and although plasma/
serum zinc levels are not reliable indicators of total organismal
zinc status,23 plasma zinc speciation and dynamics should not
be disregarded, as it may not only influence overall organismal
zinc distribution, but also modulate important bio-molecular
interactions in the bloodstream.24,25 It is also important to note
that although the levels of total plasma zinc are usually main-
tained at fairly constant levels, there are a number of conditions
where they are significantly decreased, including during the
acute phase response to infections and inflammation,26,27 and
in response to stress, for example during surgery.24 There are
also a number of chronic conditions that are associated with low
plasma levels of zinc, including asthma and type 2 diabetes.6,25
The molecular causes for the latter observations are not well
understood.28
Along with a great many studies on total metal contents of
plasma and sera,29 research concerning Zn2+–protein interactions
that dominate plasma zinc speciation has been ongoing for several
decades.30–34 Serum albumin, a 66 kDa globular protein (Fig. 1), is
the most abundant serum protein (0.6 mM), has high-nanomolar
to low-micromolar affinity for Zn2+ and is the major carrier of
plasma zinc.35,36 Metal binding occurs at an inter-domain site
involving tetrahedral metal coordination by His67, His247,
Asp249 and a fourth non-protein ligand such as a water molecule
(site A; Fig. 1c).37 Under normal conditions, albumin is the
dominant Zn2+ chelator, binding between 75–90% of the total
plasma zinc.14 Albumin-bound Zn2+ constitutes the largest part of
the so-called exchangeable zinc pool (EZP), which comprises up to
90% of the total plasma zinc. Albumin is also known to transport
various other small molecules, including pharmaceuticals,38,39
various hormones, bilirubin, and free (non-esterified) fatty acids
(FFAs).40 The binding of long-chain FFAs to albumin (Fig. 1b) has
been demonstrated to decrease the binding affinity of albumin for
Zn2+.41 The underlying molecular mechanism (Fig. 1) has been
Fig. 1 Serum albumin is a key transporter of metal ions and ‘free’ fatty acids (FFAs) in the blood plasma of all mammals. (a) Four prominent metal ion
binding sites have been identified on albumin: site A, Cys34, the N-terminal binding site (NTS) formed by an ATCUN (amino-terminal copper- and nickel-
binding) motif, and site B (location unknown); (b) seven free fatty acid (FFA) binding sites have been identified by X-ray crystallographic studies of albumin
complexed with palmitic (hexadecanoic) acid (PDB 1E7H). The three high affinity sites47 are identified with arrows. (c) Coordination of a free fatty acid
(FFA, myristate; PDB 1BJ5) at site FA2 leads to disengagement of His67, His247 and Asp249 from metal binding at site A (PDB 5IJF), preventing
coordination of Zn2+.37,49
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studied in depth using X-ray crystallography,37,42,43 molecular
modelling, NMR spectroscopy,44 and isothermal titration
calorimetry,41,45 and is now well-understood in chemical model
systems.46 Interdependence of Zn2+ and FFA binding is due to
the proximal location of the primary Zn2+ binding site (site A)
and one (out of three;47 Fig. 1b) high affinity fatty acid binding
site (FA2), both situated at the interface of domains I and II of
albumin. Upon fatty acid binding, providing the fatty acid is of
sufficient chain length, a ‘spring-lock’ allosteric switching
mechanism is invoked in albumin, disengaging amino acids
involved in Zn2+ coordination at site A, resulting in a significant
decrease in metal binding affinity, and hence this otherwise
major binding site is no longer available to Zn2+.48 In FA2, FFAs
bind with their carboxylate headgroup to Arg257 in domain II.
The allosteric switch is elicited by FFAs with 10 or more carbon
atoms,42 whilst no analogous X-ray crystal structures with bound
octanoate are available. Molecular modelling had suggested that
octanoate may fit into the half-pocket in domain II, without the
need to align the half-pocket in domain I.41 The affinities of the
three high-affinity sites cannot be distinguished; therefore, all
three sites become occupied simultaneously.47 Consistent with this
finding, our previous work has shown that myristate affects the
Zn2+ affinity of both BSA41 and HSA45 already at 1 molar equivalent
(mol. eq.). The latter concentration is within a normal physiological
range (0.1–2 mol. eq.), but FFA levels can rise to 4–6 mol. eq. in a
range of conditions (strenuous exercise, diabetes, cardiovascular
disease, non-alcoholic fatty liver disease).47
As a result of this finding, it has been suggested that
fluctuations in the levels of FFAs in the blood may impact zinc
speciation, with several downstream effects predicted.14,46,48
Although cellular zinc uptake and compartmentalisation is
largely governed by membrane-bound transporters of the ZIP
and ZnT families,50,51 it is conceivable that plasma speciation
could impact the uptake of Zn2+ by endothelial cells and blood
cells, including leukocytes involved in immune function.13 In
this regard, the effects of zinc on immune cells are of high
relevance, since zinc is required for both innate and adaptive
immune response, modulating cytokine secretion,52 and playing
roles in T cell maturation53 and B cell response to vaccination.54
For these reasons, it is of interest to study the effect of FFAs on
zinc speciation in plasma. The most basic and rapid separation
method to address zinc speciation in serum or plasma is
ultrafiltration,55–57 which allows for distinction between
protein-bound Zn2+ (the high-molecular weight fraction, including
serum albumin) from both ‘free’ (aquated) Zn2+ and Zn2+ bound to
small ligands, such as free amino acids. The low-molecular weight
fraction does usually not exceed 1% of total serum or plasma zinc,
for which a typical free Zn2+ concentration has been estimated at
around 2–4 nM, using the Zn2+-responsive dye ZnAF-2.58 The high-
molecular weight fraction also consists of non-exchangeable zinc,
bound firmly to proteins such as a2-macroglobulin (ca. 10–20%
of total plasma zinc) and retinol-binding protein.59 It is also
worth noting that the concentrations of zinc-dependent enzymes
(which are also expected to mostly contain non-exchangeable
zinc) present in plasma are so low that so far, they have mostly
escaped quantitation.
The baseline numbers given above, both in terms of total
plasma or serum zinc as well as in terms of speciation, do
not reflect the fairly dramatic changes in overall organismal
zinc distribution, or the possibility for re-distribution between
different plasma proteins under abnormal conditions. Specia-
tion studies involving metal–protein complexes have recently
been encompassed under the term ‘‘metalloproteomics’’,
which aims to combine established proteomic techniques with
complementary methods for analytical detection of metal ions.
These typically comprise separation (most commonly chroma-
tography or electrophoresis) and identification (often mass
spectrometry) steps. Techniques such as SDS-PAGE, western
blotting, and more recently native SDS-PAGE,60 have been
combined with elemental analysis, using sensitive techniques
including inductively-coupled plasma mass spectrometry (ICP-
MS) and ICP-OES (optical emission spectroscopy) to identify
and quantify metal ions.61,62 Further methodological refine-
ments include the use of laser ablation (LA-ICP-MS) as well as
isotope quantification in biological systems.63–66 Hyphenated
liquid chromatography methods, including capillary and nano-
flow HPLC,63 have attracted attention owing to the relative ease
and speed of sample throughput in combination with low-
nanomolar quantitation limits associated with ICP-MS. Serum
metalloproteomes have been previously investigated using
mass spectrometry to identify both metal ions (ICP-MS) and
tens of metal-binding serum proteins (LC-MS/MS).67 ICP-MS
has also been used to inspect variations in the levels of free metal
ions in serum obtained from patients with bipolar disorder under-
going different treatments.68 Other researchers have employed size
exclusion chromatography (SEC) paired with ICP-MS/AES to study
metal binding to plasma proteins,69–73 and the effect of chelating
agents on plasma metal speciation.74,75
In this study, we have also utilised SEC in conjunction with
offline ICP-MS analysis to investigate zinc speciation changes
in foetal calf serum (FCS) and human blood plasma, upon
addition of free fatty acids (FFAs). By administering controlled
concentrations of fatty acids to human blood plasma (and a
simple model systems), we show how FFAs are able to modulate
extracellular zinc speciation in a quantitative manner. Immobilised
metal affinity chromatography (IMAC) was employed as a comple-
mentary technique to identify key Zn2+-binding proteins in plasma
samples which may be involved in such changes in zinc speciation.
Methods
Materials
Ammonium acetate (99.999% trace metals basis), ammonium
hydroxide (28% NH3 in H2O, Z99.99% trace metals basis),
bovine serum albumin (low endotoxin, lyophilized powder,
BioReagent, suitable for cell culture, Z98% by agarose gel
electrophoresis), sodium myristate and sodium octanoate were
purchased from Sigma Aldrich UK. Foetal calf serum (FCS, lot
70428, heat-inactivated, non-USA origin) was purchased from
Labtech International UK, and a single lot was used throughout
all experiments. Citrated human plasma was purchased from
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TCS Biosciences UK. Inorganic Ventures ICP-MS standards for
Zn (1000 ppm) and Er (1000 ppm) were purchased from Essex
Scientific Supplies UK. Nitric acid (72% v/v) was freshly distilled
before use. Water used for all experiments was doubly deionised
(Type-I) Milli-Q water. All other reagents were purchased from
Sigma Aldrich UK and used as received, unless specified
otherwise.
Size exclusion chromatography (FPLC)
Experiments were carried out using a GE Healthcare A¨KTA
purifier 10 FPLC fitted with a Superdex G-75 16/60 size exclu-
sion column (13 mm average particle size, optimum separation
range 3000–70 000, column volume 120 mL), Frac-950 fraction
collector, pH/C probe 900, UV900 detector, and a P-900 pump,
with ammonium acetate buffer (50 mM, pH 7.8  0.1, adjusted
using ammonium hydroxide) mobile phase (277 K). A flow rate
of 1 mL min1 and an injection volume of 0.5 mL was used. All
samples were prepared at physiological concentrations (600 mM
BSA + 20 mM Zn2+ in 50 mM ammonium acetate buffer pH 7.8,
or neat serum), incubated for a minimum of 18 h at 310 K
before analysis, and diluted 2-fold in ammonium acetate buffer
before filtration using a 0.22 mm syringe filter. Samples were
analysed in triplicate. FPLC data were acquired and analysed
using UNICORN 5.11 for Windows. Experiments were repeated
with the following modifications: (i) bovine serum albumin
(BSA) was prepared with 0–5 mol. eq. fatty acid: octanoate (C8)
or myristate (C14). Solutions of (ii) foetal calf serum and (iii)
human citrated plasma were used in place of BSA, with and
without FFAs, but no additional zinc. Natively present zinc was
quantified separately using ICP-MS prior to use. Chemical
concentrations in final samples were 300 mM BSA (or 50% of
FCS or human plasma, as appropriate), 10 mM Zn2+, 0–1.5 mM
(0–5 mol. eq.) FFA.
Inductively-coupled plasma mass spectrometry (ICP-MS)
Zinc concentrations were determined using an Agilent 7900
series ICP-MS in He-gas mode with an internal standard
of 166Er (Agilent Technologies, USA). Calibration standards
(1–1000 ppb) were freshly prepared in either ammonium acetate
(50 mM) buffer or 3.6% ultrapure nitric acid, depending on the
nature of the samples in order to match the sample matrix. Data
were acquired and analysed using MassHunter 4.3 (Agilent
Technologies, USA).
Monitoring levels of non-protein bound Zn2+ concentration
using FluoZin-3
Briefly, a 96-well plate was washed thoroughly using 50 mL of
EDTA solution (50 mM) per well, followed by washing using
Milli-Q (Type I) water (8  200 mL) and thoroughly dried. For
the experiments involving fatty acids, two BSA concentrations
were employed (60 and 600 mM). Solutions of de-metalated BSA
(pre-treated with Chelex-100 resin to remove any potential
traces of Zn2+) were prepared (1.2 mM or 120 mM, 2 final
concentration) in ammonium acetate buffer (50 mM, pH 7.8) in
the presence and absence of sodium myristate or sodium
octanoate (1, 3 or 5 mol. eq.). The pH was adjusted to 7.8 using
ammonium hydroxide. After 24 h incubation (310 K), 100 mL
aliquots were added per well to a 96-well plate. Separately, an
80 mM (4 final concentration) solution of Zn2+ (from ZnSO4)
was prepared in ammonium acetate buffer (Zn2+ concentration
determined by ICP-MS). To each BSA-FFA condition was added
either 50 mL of Zn2+ (80 mM) or 50 mL of buffer (0 mM Zn2+).
Calibration standards for Zn2+ (0.001–40 mM) were separately
prepared in 50 mM ammonium acetate buffer (150 mL), in the
absence of BSA. To each well FluoZin-3 solution (50 mL;
0.1–2 mM, final concentration) was then added, to give a final
volume of 200 mL. Final working concentrations of samples were
60–600 mMBSA, 0–20 mMZn2+ and 0–3 mM (up to 5 mol. eq.) FFA.
Individual compositions are given in the respective Figure
captions. All samples were prepared in triplicate. After 30 min
incubation at 310 K, fluorescence was measured using a Promega
GloMax fluorescence microplate reader (blue optical kit, reagent
Ex/Em = 494/516 nm). Data were analysed and processed using
Microsoft Excel. Arithmetic means and standard deviations were
calculated, and statistical significance was evaluated using a two-
tailed t-test assuming non-equal variances (Welch’s t-test).
Albumin quantitation using bromocresol green
Albumin quantitation of FCS and human citrated plasma was
carried out using a commercial bromocresol green (BCG)
colorimetric assay kit (Abcam, ab235628) according to the
manufacturer’s instructions. Samples were diluted 1 : 100 in
assay buffer before analysis and read using a Promega GloMax
microplate reader (absorbance at 620 nm).
Determination of fatty acids by GC-MS
Fatty acids were extracted from FCS using chloroform :methanol
(2 : 1 v/v, 1 mL reagent per 100 mL serum) with vortexing, as
described by the Folch method.76 The layers were separated
using centrifugation, and the chloroform layer was evaporated to
dryness. Lipid samples were dissolved using 90 mL of chloro-
form :hexane (1 : 1, Folch extractant) and derivatized with 10 mL
Meth-Prep II (methanolic m-trifluoromethyl-phenyltrimethyl-
ammonium hydroxide) at room temperature for 30 min. Samples
were analysed using an Agilent Technologies GC-MS (7890B GC –
5977B MS), operated in EI mode (70 eV), fitted with an Agilent
19091S-433, HP-5MS (5% phenyl methyl siloxane) 30 m 
250 mm  0.25 mm column with helium carrier gas. Temperature
gradient: initial: 50 1C (1 min), increased to 280 1C at a rate of
20 1C min1, then 7.5 min hold time. Total run time: 20 min.
Immobilized metal affinity chromatography (IMAC)
1 mL IMAC FF columns (packed with IMAC Sepharose Fast Flow
resin; GE Healthcare, UK) were prepared as described by the
manufacturer and either charged with Zn2+ or left un-charged.
Columns were equilibrated with 10 mM HEPES (pH 7.2, 0.5 M
NaCl) ready for application of plasma. Human citrated plasma was
clarified by centrifugation at 12000  g for 5 minutes and the
supernatant was passed through a 0.22 mm filter. 1 mL of clarified
plasma was applied to each column and the flow-through (FT)
fraction was collected. Unbound protein was washed through the
column using 6  1 mL of buffer containing 2 mM imidazole,
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before bound proteins were eluted using 2  1 mL of 20 mM
imidazole buffer and 2  1 mL of 200 mM imidazole buffer.
SDS-polyacrylamide gel electrophoresis
Samples from SEC and IMAC fractions were mixed with an
equal volume of (2) Laemmli buffer (Sigma-Aldrich) and
heated to 80 1C for 5 minutes before loading onto mini-
Proteans TGXt precast gels (4–15% resolving gel percentage;
20–250 kDa separation range; Bio-Rad, UK),77 which were run
in standard Tris-glycine buffer following the manufacturer’s
instructions. Gels were stained using Coomassie brilliant blue
R-250 (National Diagnostics, USA).
Western blotting
Proteins were transferred onto a nitrocellulose membrane
using a semidry blotting assembly (90 min, 150 mA). Non-
fatty milk solution (2.5 g of non-fatty milk powder in 50 mL of
Tris-buffered saline with 0.1% Tween 20; TBST) was used as
blocking reagent (1 h at 277 K). The membrane was washed
with TBST buffer before adding Anti-HRG primary antibody
(produced in rabbit, Sigma-Aldrich, 10 mg mL1 in 20 mL TBST
buffer, 1 hour). After further washing with TBST buffer, 20 mL
solution of anti-rabbit IgG alkaline phosphatase conjugate
secondary antibody (Sigma-Aldrich) was added and incubated
for 1 h. The membrane was washed three times with TBST
buffer after every 5 min of rocking. Finally, 2 mL of Novexs AP
chromogenic substrate (Invitrogen) was added and incubated
for 15 min. After rinsing with water, gels were imaged using an
ImageQuant LAS4000 Blot Imaging System (GE Healthcare Life
Sciences, Pittsburgh, USA).
Peptide mass fingerprinting
Protein bands of interest were cut from SDS-PAGE gels with a
scalpel blade and were subjected to in-gel tryptic digestion
using a commercially produced kit (Pierce, Thermo Scientific,
UK). The masses of the generated peptides were determined
by MALDI-TOF MS analysis. Briefly, 2 mL of sample matrix
(10 mg mL1 a-cyano-4-hydroxycinnamic acid in 50% aceto-
nitrile, 0.1% trifluoroacetic acid) was mixed with an equal
volume of sample and pipetted onto a steel MALDI-target plate.
A Bruker Ultraflex II MALDI-TOF/TOF mass spectrometer
(Bruker Daltonics, UK) with a 337 nm laser and operated
in reflectron mode was used to measure the peptide masses.
Mass calibration was performed with a PEG2000 MALDI-MS
standard, and mass accuracy was verified using Bradykinin and
Substance P peptide standards. Internal mass accuracy was
further confirmed with the presence of the autolytic trypsin
peaks of 845.2 and 2211.1 Da. Peptide masses were acquired
over the range of 800–3500 Da, and mass lists were generated
using Bruker Flex-analysis software with default parameters,
and searched against the NCBI database using Mascot (Matrix
Science, UK). The following search criteria were selected: fixed
modification of carbamidomethyl on cysteine, variable modification
of oxidation of methionine, maximum of 1 missed cleavage,
o50 ppmmass accuracy, ‘‘Homo sapiens’’ was selected for taxonomy.
Only searches giving significant MOWSE (MOlecular Weight SEarch)
scores were recorded.
Results and discussion
Zinc speciation in serum and plasma is affected by free fatty
acids (FFAs)
Zinc speciation methodology was first optimised using a simplified
single-protein system containing bovine serum albumin (BSA), in
the absence of FFAs. A Superdex G-75 16/60 FPLC-SEC column was
employed for size exclusion chromatography, with the selection of a
mobile phase which was compatible with both SEC under near-
native conditions and direct elemental analysis by ICP-MS (50 mM
ammonium acetate, pH 7.8). Physiological concentrations of BSA
(600 mM) and Zn2+ (20 mM) were analysed after 2-fold dilution to
ensure sufficiently high concentrations of metal ions were present
in the eluent for quantitation by ICP-MS whilst minimizing deposi-
tion of non-volatile salts on the sampling cone in the subsequent
experiments with serum and plasma. The method was shown to
have high reproducibility in both FPLC-SEC (A280nm) and ICP-MS
(66Zn) datasets (Fig. S1 and S2, ESI†), with 109.9% recovery of
protein-bound Zn2+ from the original 20 mM sample. Data were
then acquired in the presence of two different FFAs, octanoate (C8)
and myristate (C14). In both instances, the chromatography traces
for protein (A280nm) did not statistically differ from the FFA-free
control, suggesting that BSA elution (or later, serum protein
elution) was not significantly affected by the presence of FFAs
(Fig. S3, ESI†). However, ICP-MS analysis of SEC fractions deter-
mined that 5 mol. eq. of myristate significantly decreased the
amount of albumin-bound Zn2+ by 69.9% (from 20 mM to 6.02 mM)
relative to the FFA-free control (Fig. 2a). In contrast, 5 mol. eq. of
octanoate had no significant effect on the concentration of Zn2+
in albumin-containing fractions (Fig. S4, ESI†). This is in agree-
ment with previous crystallographic72 and molecular modelling
studies,41 which suggested that FFAs with a chain lengthrC8 are
too short to elicit the allosteric switch on albumin. Previous ITC
experiments had confirmed that octanoate indeed did not affect
the Zn2+-binding capacity of BSA.41 In contrast, site A in both BSA
and HSA45 was demonstrated to be essentially absent in the
presence of 5 mol. eq. of myristate. Residual weak Zn2+-binding
capacity was still observed from a secondary Zn2+-binding site on
both bovine (K2(ITC)E 1.4 104 M1; ionic strength = 95 mM) and
human albumin (K2(ITC)E 3 103 M1; ionic strength = 183 mM),
assumed to be site B based on previous 111Cd NMR competition
studies.41,78 A possible secondary Zn2+ binding site has been
observed by crystallography of equine serum albumin, involving
His9, Asp13 and Asp254, all of which are fully conserved in HSA and
BSA. This, in principle, justifies the observation of a ca. 70%
reduction in albumin-bound Zn2+. It must also be considered
that the composition of our buffer (50 mM ammonium acetate)
has significantly lower ionic strength (o50 mM) than either
previously employed experimental conditions or physiological
media (4100 mM), which is expected to increase complex stability
and hence the proportion of Zn2+ bound to BSA in our model
system used for offline LC-ICP-MS.
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Foetal calf serum (FCS) is a common component of extra-
cellular media for the culture of in vitro cell lines, and provides
a more complex system for chromatographic analysis. First, the
albumin content of FCS was quantified using bromocresol
green, (345  65 mM). This is lower than physiological albumin
levels in adult humans (B600 mM); however the comparable
total zinc concentrations of FCS and plasma (25.8  0.3 mM and
21.4  0.4 mM, respectively) mean that albumin is in excess to
zinc in both instances. Size exclusion chromatography experi-
ments were repeated using FCS in place of bovine albumin. In
this complex medium, five mol. eq. of myristate did not impact
the cumulative recovery of zinc relative to the initial sample (i.e.
no ‘free’ Zn2+ released, unlike in the BSA model system).
Rather, the presence of myristate invoked a re-distribution of
zinc, predominantly to higher molecular weight (lower elution
volume) species (Fig. 2b). Data obtained in the presence of
sodium octanoate (C8) in FCS confirm that octanoate did not
impact either the distribution of serum zinc or cumulative
zinc recovery (Fig. S4, ESI†). Thus, for both short-chain and
long-chain fatty acids, the system BSA + fatty acid + Zn2+
behaves in a similar way in this complex medium (FCS) as in
the pure ternary mixture, with the main difference being the
destination of the Zn2+ liberated from albumin.
Direct comparison of data acquired for BSA and FCS in the
absence of myristate indicates that Zn2+ in FCS is not solely
bound by albumin, with ca. 12.6% eluting together with higher
molecular weight proteins. This is in line with expectations, as
the known Zn2+-binding protein a2-macroglobulin has been
identified in commercial preparations of foetal calf serum.79 It
is also important to note that FCS already contains native FFAs.
After chloroform:methanol extraction and derivitisation of
FFAs using a methanolic solution of m-trifluoromethyl-
phenyltrimethylammonium hydroxide, GC-MS analysis princi-
pally identified palmitic (C16:0), stearic (C18:0) and oleic acids
(C18:1) in FCS (Fig. S5, ESI†), all of which are known to bind to
FA2.42,80 One must therefore consider that the fatty acid bind-
ing sites of albumin are likely to be already partially occupied,
and this may further contribute to the wider distribution of
Fig. 2 Offline SEC-ICP-MS (Superdex G-75 16/60 FPLC) analysis demonstrates that sodium myristate (3 mM, 5 mol. eq.) impacted zinc speciation in:
(a) bovine serum albumin, where the Zn2+ binding capacity of BSA is significantly reduced, resulting in decreased cumulative protein-bound zinc.
For both foetal calf serum (b) and human citrated plasma (c), cumulative protein-bound zinc was not significantly affected, but instead, zinc was
re-distributed amongst other plasma/serum proteins with Zn2+ binding capability. *Protein-bound zinc only. The black lines in the chromatograms
refer to protein elution, monitored by UV absorption at 280 nm, whilst the yellow and blue bars refer to zinc concentrations measured by ICP-MS. In the
right-hand plots, black lines connecting the experimental data are drawn to guide the eye.
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Zn2+ relative to the pure binary albumin + Zn2+ system. As a
further consequence, the redistribution observed after in vitro
FFA supplementation may be less dramatic, compared to the
model system involving (FFA-free) BSA. However, in FCS, Zn2+ is
likely to be bound to other proteins that happen to also elute in
the same fractions as albumin, which could not be resolved by
the SEC column.
The concentration of non-albumin bound Zn2+ in eluates
from the simple BSA + myristate model system was not quanti-
fiable by SEC-ICP-MS because the released Zn2+ did not elute in
the small-molecule fraction. However, repeated elution of the
Superdex column using EDTA (20 mM) demonstrated signifi-
cant stationary-phase retention of Zn2+ (Fig. S6, ESI†). The data
shown in Fig. 2 were obtained after rigorous pre-cleaning of the
column with 20 mM EDTA, which enabled reasonable recovery
(110%) of zinc in the absence of myristate. Ideally, speciation
analysis should provide quantitation across all species, hence
an alternative method to capture non-protein-bound zinc in the
various systems was desirable.
Monitoring Zn2+ release from albumin by FluoZin-3
Attempts were made to quantify the proportion of non-albumin
bound zinc in presence and absence of myristate using a
fluorescent Zn2+ sensing reagent (FluoZin-3; FZ3 in the following
discussion). It was hoped that this approach would allow ameasure
of fatty-acid induced release of Zn2+ with minimal perturbation of
the system. FZ3 was chosen as its affinity is relatively close to that of
albumin (the conditional dissociation constant of FZ3 at pH 7.4 has
recently been refined, Kd = (9.1  0.4)  109 M),81 and FZ3 has
high selectivity for Zn2+ over other divalent metal ions such as Ca2+
and Mg2+.82 Since fluorescent sensors are typically employed at
concentrations that are much lower than those of surrounding
proteins,83–85 the influence of the sensor on the original
equilibrium should be relatively small. Other Zn2+ sensors were
considered, but rejected based on their documented tendency
to form ternary complexes with Zn2+ and proteins.85–87
The response of either 0.1 or 2 mM FZ3 to [Zn2+] was
recorded in ammonium acetate buffer using a range of defined
Zn2+ concentrations (Fig. S7, ESI†), before exploring the effect
of BSA concentration on FZ3 fluorescence (Fig. S8, ESI†). We
found that BSA promoted FZ3 fluorescence in the absence of
Zn2+; this suggested that BSA had the ability to bind FZ3.
Indeed, fluorescein and related xanthene derivatives have pre-
viously been shown to bind to albumin;88–90 thus analogous
interactions with the structurally similar fluorescent moiety in
FZ3 are unsurprising. In the presence of Zn2+, the fluorescence
decreased with increasing BSA concentration. This trend was
expected, as increasing [BSA] should decrease the amount of
free [Zn2+]. However, the fluorescence at 600 mM BSA and 2 mM
FZ3 in presence and absence of 20 mM Zn2+ was identical
(Table S1, ESI†), indicating that under these conditions, FZ3
was not able to report on Zn2+, free or protein-bound. At lower
BSA concentrations, readings also deviated significantly from
estimates based on published equilibrium constants, most
likely due to the formation of ternary complexes and also FZ3
abstracting BSA-bound zinc, which becomes significant at
lower [BSA] (Fig. S9, ESI†). Hence, due to the number and
complexity of the various equilibria and processes in operation,
the recorded fluorescence response could not be linked in a
systematic manner to free [Zn2+]. Our observations are consis-
tent with those of others who have highlighted the pitfalls in
quantitation of free [Zn2+] using fluorescent dyes such as
Zinquin,86,87 TSQ,86 ZnAF dyes,91 and indeed FluoZin-3.92 Pro-
blems have been attributed to ternary complex formation and
other interactions with proteins86,87 and low-molecular weight
components of physiological media.91,92 Our observations and
the latter study suggest that the previously cited low nanomolar
free [Zn2+] determined for plasma58 should be revisited.
Although the presence of BSA thus hindered the use of FZ3
to quantify non-protein bound Zn2+ in absolute terms, the
effect of fatty acids was studied at lower BSA (60 mM) or FCS
(10%) concentrations, employing the higher FZ3 concentration
(2 mM), which was found to leave sufficient free FZ3 to respond
to liberated Zn2+ (Fig. 3). FFAs were also confirmed to not affect
background FZ3 fluorescence (Fig. S10, ESI†). Most importantly,
there was a clear trend for myristate-induced Zn2+ release in the
simple systems with BSA that was not observed with octanoate,
essentially mirroring the observations from offline SEC-ICP-MS
(Fig. 2). Myristate-induced Zn2+ release was also observed for the
FCS systems. This indicates that FZ3 is able to also compete with
the ‘Zn2+ acceptor’ proteins apparent in the SEC data. Given that
the FZ3 concentration (2 mM) and affinity for Zn2+ are both
Fig. 3 Measurement of FluoZin-3 (2 mM) fluorescence in the presence of either: (a) 60 mM BSA + 20 mM Zn2+ or (b) 10% FCS; with additional free fatty
acids (FFAs). Myristate (black) increases the fluorescence of FluoZin-3, in contrast to the short-chain fatty acid octanoate (white), which had no significant
effect on fluorescence. Statistics carried out using a two-tailed t-test assuming unequal sample variance (Welch’s t-test), *Po 0.05, **Po 0.01. See ESI†
for full statistical analysis.
Metallomics Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
O
ct
ob
er
 2
01
9.
 D
ow
nl
oa
de
d 
on
 8
/1
1/
20
20
 1
:5
6:
30
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
1812 | Metallomics, 2019, 11, 1805--1819 This journal is©The Royal Society of Chemistry 2019
expected to be higher than those for most of these proteins, this
observation is qualitatively in line with expectations. In FCS,
unlike for BSA alone, fluorescence was also increased by the
addition of octanoate (Fig. 3). We suggest that this is likely due to
the presence of intrinsic FFAs in serum (Fig. S5, ESI†), which
may be re-distributed amongst the 7 principal FFA binding sites
of albumin, upon addition of further equivalents of FFA. This, in
turn, may lead to the (partial) population of site FA2 by longer-
chain intrinsic FFAs, leading to the release of Zn2+ from site A.
We also note that fluorescence readings for the 10% FCS systems
are higher than for the 60 mM BSA systems throughout, in line
with the significantly lower BSA concentration in FCS (ca. 35 mM,
according to quantitation with bromocresol green; vide supra).
The potential Zn2+ acceptor protein HRG is present in SEC
fractions with FFA-promoted increases in [Zn]
Albumins from different species are known to bind Zn2+ at site
A with subtle variance in their affinities, and published values
concerning the differences in the Zn2+ affinity of human
and bovine albumins are often conflicting, though both are
generally accepted to be in the sub-micromolar range.93,94
Given the wide-ranging involvement of both zinc and fatty
acids in various pathological diseases in humans, not limited
to Type 2 diabetes,25 coronary heart disease,6 thrombosis,45 and
Alzheimer’s disease,95,96 we also investigated the impact of
FFAs on zinc speciation in human citrated plasma, containing
human serum albumin (HSA), using the previously described
methodology. Using SEC and ICP-MS, a similar re-distribution
of zinc to larger human plasma proteins with Zn2+-binding
capability (smaller elution volume) was clearly apparent, analogous
to our findings in FCS (Fig. 2c). It was therefore of interest to
identify such proteins, and identify target molecules which (a)
display significant Zn2+-binding ability under physiological
conditions, and (b) are larger than serum albumin (i.e. have
shorter retention times in size exclusion chromatography).
Plasma is known to contain tens of thousands of proteins,97
and while the resolution of our SEC ICP-MS method is sufficient
to clearly demonstrate a re-distribution of zinc to protein(s) of
higher molecular weight, it is not sufficient to directly identify
individual (zinc-binding) proteins, as seen by two broad bands in
the chromatograms of both FCS and human plasma (Fig. 2).
Complementary techniques (SDS-PAGE, western blotting) were
therefore employed as a further step of protein identification in
the eluent fractions.
Previous work from our team has suggested that such
re-distribution may involve human histidine-rich glycoprotein
(HRG), which has the capacity to bind up to ten Zn2+ ions (K =
1.63  105).45 In human plasma, HRG is present at low micro-
molar (1.3–2.0 mM) concentrations.98 The ca. 72 kDa serum
protein exists as a native dimer and was successfully identified in
elution volumes 43–53 mL of human plasma from size exclusion
fractions by western blotting and immunodetection using HRG-
specific antibodies (Fig. 4; 66 kDa albumin eluted predominantly
between 49 and 61 mL). HRG is principally involved with the
regulation of blood coagulation, but is also associated with angio-
genesis and cell proliferation.98 The histidine-rich region (HRR) of
HRG is known to complex Zn2+, and upon Zn2+ coordination,
the affinity of the HRG-Zn2+ complex for heparin (a well-known
anticoagulant) is known to increase.99 For this reason, we suggest
that zinc speciation may be the ‘missing link’ between blood
clotting disorders and elevated levels of fatty acids (leading to the
re-distribution of Zn2+ from albumin to proteins associated with
blood clotting, affecting their function).100 The greater affinity
of the Zn2+-HRG complex for heparin prevents heparin from
inhibiting clot formation,101 and hence Zn2+ is an important
regulator of heparin neutralisation.102 Though HRG detection
does coincide with fractions associated with increased [Zn2+]
after redistribution of plasma zinc, we emphasise that HRG is
only one of potentially hundreds of possible acceptor proteins
in the aforementioned fractions. It is quite likely that many
other proteins in these fractions also have affinity for Zn2+.
Summarily, it is evident that in human plasma, like in FCS, Zn2+
ions liberated from albumin remain largely protein-bound,
rather than occurring as ‘free’ aquated ions or in complexes
with small molecules such as histidine or glutathione.
Immobilized metal ion affinity chromatography to identify Zn2+
binding proteins
As indicated, 1D-size exclusion chromatography cannot resolve
and identify single proteins which may participate in the
re-distribution of Zn2+ from albumin. We therefore looked to a
complementary chromatographic method: immobilized metal
ion affinity chromatography (IMAC). This technique requires
surface-exposed metal sites, and so should be ideally suited to
capture proteins with sites that are involved in the ‘‘exchangeable
zinc pool’’. Proteins from unfractionated human plasma were
captured on a Zn-IMAC column, eluted with imidazole, further
separated by SDS-PAGE (Fig. 5a) and identified by peptide mass
fingerprinting (Table 1). Plasma was also applied to a column
Fig. 4 Human serum albumin (HSA, 66 kDa) identified in fractions 49–61mL
by SDS-PAGE (Coomassie staining), and histidine-rich glycoprotein (HRG,
72 kDa) in fractions 43–53 mL, identified by western blotting and immuno-
detection using specific HRG antibodies. Data for protein content (A280) and
zinc distribution (in the presence and absence of myristate) obtained using
SEC-ICP-MS have been overlaid using data from Fig. 2c.
Paper Metallomics
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
O
ct
ob
er
 2
01
9.
 D
ow
nl
oa
de
d 
on
 8
/1
1/
20
20
 1
:5
6:
30
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2019 Metallomics, 2019, 11, 1805--1819 | 1813
that had not been charged with any metal ions to check for any
non-specific binding to the resin (Fig. 5c), and in this case no
proteins were found to be retained on the column.
Sensitivity is a clear limitation of a 1D SDS-PAGE approach,
however comparison with the uncharged gel demonstrates that
several proteins were selectively enriched in the fractions eluted
with 20 and 200 mM imidazole. Molecular weights ranged
between 16 and 165 kDa (Table 1). Identified proteins also
included haemoglobin, likely due to partial lysis of erythrocytes
during the plasma manufacturing process. The remaining
entries mostly refer to known high-abundance plasma proteins.
A large quantity of the most abundant serum protein,
human serum albumin (HSA) was observed in all fractions,
evidenced by western blotting and immunodetection using HSA
antibodies (Fig. 5b). Interestingly, comparison of the gels for
Zn-loaded and Zn-free IMAC demonstrates that the occurrence
of HSA across all fractions is not a mere consequence of its high
abundance, since the albumin-related bands are very faint in
either wash or elution fractions from the metal-free IMAC
column (Fig. 5c). In contrast, albumin was present in both
wash and elution fractions of the Zn-charged column (Fig. 5a).
Nonetheless, most albumin was found in either flow-through or
wash fractions, indicating a rather low affinity of HSA for a
Zn-IMAC column. This finding can be understood when the
locations and structures of the known metal binding sites in
HSA are considered: site A (the major Zn2+-binding site) is not a
surface site, but is partially buried between domains IA and IIA
(Fig. 1). The interaction of this site with immobilised Zn2+ is
therefore sterically unlikely. It might be envisioned that partial
unfolding of albumin might lead to exposure of the two half-
sites, but since these are only composed of either one (His67) or
two (His247 and Asp249) residues, this would not generate a
strong interaction with the column either. Another known
binding site is the N-terminal ATCUN motif, which is the
primary binding site for Cu2+ and Ni2+. Although Zn2+-
binding has been demonstrated for short peptide mimics of
this motif, the affinity of this site for Zn2+ at neutral pH is
rather weak.37,103 Furthermore, calorimetric and crystallo-
graphic evidence of a secondary Zn2+ site of equine albumin,
involving His9, Asp13 and Asp254 (fully conserved in HSA),
37
might present a possible candidate for the secondary Zn2+
binding site (site B). This site is more exposed than site A,
therefore its contribution to the IMAC affinity of albumin
cannot be ruled out. However, its affinity for Zn2+ is almost
Fig. 5 Fractions from IMAC chromatography on a Zn-charged column (a) analysed using western blotting and immunodetection (b) with antibodies
against HSA and HRG. For comparison, fractions from a metal-free IMAC column are shown in (c). FT = flow-through.
Table 1 Homo sapiens plasma proteins binding to Zn-IMAC columns, identified by peptide mass fingerprinting using Mascot to search results against
the NCBI database. Only searches with significant MOWSE (MOlecular Weight SEarch) scores were recorded
Protein Mass/kDa Peptides matched Sequence coverage (%) MOWSE score
Haemoglobin subunit b 16.1 9 76 90
Immunoglobulin light chain 28.1 10 63 81
Haptoglobin 38.7 14 35 113
Chain B IgG1 Fc fragment 23.9 5 37 75
Immunoglobulin heavy chain 42.4 12 30 72
Albumin 70.6 16 31 119
Complement C3b 71.2 26 47 240
Chain A transferrin 77.3 34 48 228
Chain B complement C4 84.8 15 23 67
Plasminogen type II 91.1 22 34 136
Complement C3 114.2 30 33 210
Ceruloplasmin 116.2 14 16 103
a2-Macroglobulin (Zn) 164.6 44 39 279
Inter-alpha inhibitor H1 99.8 13 21 81
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2 orders of magnitude weaker than site A.45 In conclusion,
neither of the well-defined metal sites in HSA are expected to
display strong interaction with a Zn-IMAC column, although
Cu- and Ni-IMAC columns may display stronger HSA binding.67
The two most abundant Fe- and Cu-binding plasma proteins,
respectively transferrin and ceruloplasmin, were also amongst
the captured proteins. It is unknown whether their capture on
the Zn-IMAC column involves their known metal-binding sites.
Amongst the strongly enriched proteins were immunoglobulin
light and heavy chains (Table 1). Several components of the
complement system were also detected, including complement
C3 and C4. These proteins, as well as further complement compo-
nents, are in fact already known to interact with Zn2+. In particular,
Zn2+ inhibits factors I and H, and promotes protein–protein
interactions between C3 and factor H.104,105 Many of these proteins
are expected to elute in the SEC fractions with fatty-acid mediated
increases in zinc. Another protein with higher molecular weight,
a2-macroglobulin, is partially homologous to complement
proteins.106 As previously explained, a2-macroglobulin harbours
the largest proportion of non-exchangeable zinc in plasma,48 but
the site(s) responsible for this fact are likely to differ from those
responsible for the affinity to the IMAC column, as metal sites with
reasonably fast exchange kinetics are prerequisite for binding to an
IMAC column. Furthermore, isotope-exchange experiments using
65Zn indicated that a2-macroglobulin does not exchange, or bind
extra Zn2+ under relevant conditions,107 rendering it an unlikely
candidate in the re-distribution of Zn2+ from albumin.
Though histidine-rich glycoprotein (HRG) was not amongst
the proteins identified by peptide mass fingerprinting of
SDS-PAGE bands, western blotting and immunodetection
revealed the presence of HRG in the second IMAC elution
fraction (20 mM imidazole), confirming the capacity of this
protein for binding (partially complexed) Zn2+ (Fig. 5b). This
has been reported previously,108–110 and as mentioned, many
HRG activities are accepted to be Zn2+-dependent.110,111 This is
in agreement with our earlier detection of HRG in size exclusion
chromatography (SEC) fractions with increased Zn2+ after metal
re-distribution in the presence of FFAs.
Given the association between elevated plasma fatty acid
levels and the incidence of thrombotic disease,112 a possible
Zn2+ re-distribution from albumin to an important coagulation-
regulating protein suggests that the described allosteric switch,
linking plasma FFA levels and Zn2+ distribution, may have
significant implications in the progression of various cardio-
vascular disorders. Physiologically-relevant long-chain saturated
FFAs such as palmitate (C16) and stearate (C18) have even higher
affinity for albumin,45,113 and so it is likely that such an effect
would be at least as apparent, if not more pronounced, in vivo.
Furthermore, HRG has a comparatively high abundance (1–2 mM),
relative to many other plasma proteins. Considering the affinities
of HSA (K1(ITC) = 1.35  105 M and K2(ITC) = 3  103 M for site B)
and HRG (KITC 8.06  104 M) for Zn2+,45 we suggest that HRG
might be a likely candidate acceptor protein during serum zinc
re-distribution, with abundant proteins of the complement
system (C3, C3b, C4, factor H1) also being likely candidates. It
is well-known that zinc dynamics play roles in coagulation and
immune response, and therefore there must be conditions
under which associated proteins become populated with Zn2+.
Since albumin (the major Zn2+ binding plasma protein) is always
present, it too must be involved in such dynamic networks.
Furthermore, by virtue of the allosteric switch, changes in FFA
levels are hence predicted to impact on both blood coagulation
and the immune system, as a result of Zn2+ speciation changes
in blood plasma.
Conclusions
SEC combined offline with ICP-MS for the analysis of extra-
cellular fluids has provided insight into changes in Zn2+
speciation, induced by the presence of myristate, a long-chain
(C14:0) non-esterified fatty acid. This is a consequence of a now
well-established allosteric mechanism on serum albumin, the
key Zn2+ carrier protein in the bloodstream. The operation of
this molecular mechanism and its immediate consequences
were for the first time observed in complex biological systems
by chromatographic techniques, with complementary evidence
provided by the use of a Zn2+-sensing fluorescent reagent,
FluoZin-3. In pure albumin systems (i.e. in the absence of any other
Zn2+ acceptors), any Zn2+ displaced from albumin was scavenged by
the SEC resin. In foetal calf serum and human plasma, Zn2+
liberated from albumin was overwhelmingly re-distributed to other
plasma proteins that were largely of higher molecular weight than
albumin. One highly likely candidate Zn2+ acceptor protein is HRG, a
multifunctional protein whose activities are modulated by zinc
binding. Further potential Zn2+ acceptor plasma proteins were
identified by capture on an IMAC column, followed by SDS-PAGE
and peptide mass fingerprinting, and include several proteins of the
complement system.
From this, we infer that the decreased Zn2+ binding capacity
of albumin in the presence of FFAs may have significant
implications, for both normal and disease-altered physiology.
Whilst numerous pathological diseases are associated with
elevated levels of free fatty acids, not limited to cardiovascular
diseases (including thrombosis),114–116 diabetes,117–119 and
neurodegenerative diseases,120–122 FFA levels also fluctuate
during periods of intense exercise, fasting and after the con-
sumption of food.123–125 A deeper understanding of the down-
stream consequences of FFA-mediated Zn2+ re-distribution is
now required to comprehend the wider impact this may have
on organismal physiology.
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